Clinical Case Study | By Nishihira K, Asaumi Y, Kataoka Y et al.
A 42-year-old man with angina pectoris was hospitalized to undergo percutaneous coronary intervention (PCI) for a significant stenosis in the mid-left anterior descending (LAD) coronary artery (Panel A). Optical coherence tomography (OCT) and near-infrared spectroscopy (NIRS) imaging at the arrowhead site identified the presence of lipid-rich plaque, exhibiting a high maximum 4-mm lipid core burden index (max-LCBI) with the value of...
Original Research | By Fach A, Bünger S, Wienbergen H et al.
As old patients, who were treated by percutaneous coronary interventions (PCI) for ST-segment elevation myocardial infarction (STEMI), are regularly excluded or underrepresented in randomized trials, data on treatment and outcomes of this patient group at high risk have to be collected by registries. The study population of the German Bremen STEMI Registry was divided into the age groups G1: <75 years (n = 4,108, young), G2: 75 to ...
Original Research | By Dasari TW, Hamilton S, Chen AY et al.
BACKGROUND - Reperfusion therapy is lifesaving in patients presenting with ST-segment elevation myocardial infarction (STEMI). Contemporary data describing the characteristics and outcomes of patients presenting with STEMI not receiving reperfusion therapy are lacking. METHODS - Using the ACTION Registry-GWTG database, we examined 219,726 STEMI patients (January 2007-December 2013) at 721 percutaneo...
Original Research | By Pryds K, Terkelsen CJ, CONDI Investigators.
OBJECTIVE - We investigated influence of remote ischaemic conditioning (RIC) on the detrimental effect of healthcare system delay on myocardial salvage in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI). METHODS - A post-hoc analysis of a randomised controlled trial in patients with STEMI randomised to treatment with pPCI or RIC...
Original Research | By Moon J, Suh J, Kang WC et al.
Although epidemiologic studies have shown the impact of height on occurrence and/or prognosis of cardiovascular diseases, the underlying mechanism is unclear. In addition, the relation in patients with ST-segment elevation myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention (PCI) remains unknown. We sought to assess the influence of height on outcomes of patients with acute STEMI undergoing primary P...
Original Research | By Agrawal S, Garg L, Sharma A et al.
Patients with myocardial infarction admitted on weekends have been reported to less frequently undergo invasive angiography and experience poorer outcomes. We used the Nationwide Inpatient Sample database (2003 to 2011) to compare differences in all-cause inhospital mortality between patients admitted on a weekend versus weekday for an acute non-ST-segment elevation myocardial infarction (NSTEMI) and to determine if rates and timing of ...
Original Research | By Geng J, Ye X, Liu C et al.
Studies evaluating the outcomes of patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) are scarce, particularly in China. The purpose of present study was therefore to compare the impact of off-hours and on-hours admission on clinical outcomes in STEMI patients from China.We retrospectively analyzed 1594 patients from 4 hospitals. Of these, 903 patients (56.65%)...
Original Research | By Wallentin L, Lindhagen L, FRISC-II study group.
BACKGROUND - The FRISC-II trial was the first randomised trial to show a reduction in death or myocardial infarction with an early invasive versus a non-invasive treatment strategy in patients with non-ST-elevation acute coronary syndrome. Here we provide a remaining lifetime perspective on the effects on all cardiovascular events during 15 years' follow-up. METHODS - The FRISC-II prospective, ...
Clinical Trial | By YL Han, B Xu, NeoVas Randomized Controlled Trial Investigators
OBJECTIVES - The authors sought to evaluate the safety and effectiveness of the NeoVas bioresorbable scaffold (BRS) compared with metallic drug-eluting stents. BACKGROUND - BRS have the potential to improve very late outcomes compared with metallic drug-eluting stents, but some BRS have been associated with increased rates of device thrombosis before complete bioresorption. NeoVas is ...
Original Research | By Clark DJ; Melbourne Interventional Group.
BACKGROUND - Door-to-balloon time (DTBT) less than 90min remains the benchmark of timely reperfusion in ST-elevation myocardial infarction (STEMI). The relative long-term benefit of timely reperfusion in STEMI patients with differing risk profiles is less certain. Thus, we aimed to assess the impact of DTBT on long-term mortality in high- and low-risk STEMI patients. METHOD - We analysed baseline...